

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB04/004538

International filing date: 27 October 2004 (27.10.2004)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0325287.1
Filing date: 29 October 2003 (29.10.2003)

Date of receipt at the International Bureau: 19 November 2004 (19.11.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



GB04/4538



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

10 November 2004



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



29 OCT 2003

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference		T1637PV	
2. Patent application number (The Patent Office will fill in this part)		0325287.1	30OCT03 E848240-1 002639 P01/7700 0.00-0325287.1
3. Full name, address and postcode of the or of each applicant (underline all surnames)		Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom	
Patents ADP number (if you know it)		00597799001 ✓	
If the applicant is a corporate body, give the country/state of its incorporation		United Kingdom	
4. Title of the invention		Therapeutic agents	
5. Name of your agent (if you have one)		Mr. J. Horgan	
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)		Merck & Co., Inc. European Patent Department Terlings Park Eastwick Road Harlow Essex CM20 2QR	
Patents ADP number (if you know it)		07536832001 ✓	
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority Application number (if you know it)	Date of filing (day/month/year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day/month/year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:		Yes	
a) any applicant named in part 3 is not an inventor, or			
b) there is an inventor who is not named as an applicant, or			
c) any named applicant is a corporate body.			
See note (d))			

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	35
Claim(s)	0
Abstract	0
Drawing(s)	0




10. If you are also filing any of the following, state how many against each item.

Priority documents	-
Translations of priority documents	-
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	-
Request for preliminary examination and search (Patents Form 9/77)	-
Request for substantive examination (Patents Form 10/77)	-
Any other documents (please specify)	-

11. I/We request the grant of a patent on the basis of this application.

Signature


Mr. J. Horgan

Date 29 October 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr. J. Horgan

01279 440625

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Patents Form 1/77

THERAPEUTIC AGENTS

The present invention is concerned with 4-substituted-4-pyridinyl-N-[4-substitutedphenyl]piperidine-1-carboxamides and analogues and derivatives thereof as well as pharmaceutically acceptable salts and prodrugs thereof, which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).

The pharmacologically active ingredient of chilli peppers has been recognised for some time to be the phenolic amide capsaicin. The application of capsaicin to mucous membranes or when injected intradermally, causes intense burning-like pain in humans. The beneficial effects of topical administration of capsaicin as an analgesic is also well established. However, understanding of the underlying molecular pharmacology mediating these responses to capsaicin has been a more recent development.


The receptor for capsaicin, termed the vanilloid VR1 receptor, was cloned by Caterina and colleagues at UCSF in 1997 (*Nature*, 398:816, 1997). VR1 receptors are cation channels that are found on sensory nerves that innervate the skin, viscera, peripheral tissues and spinal cord. Activation of VR1 elicits action potentials in sensory fibres that ultimately generate the sensation of pain. Importantly the VR1 receptor is activated not only by capsaicin but also by acidic pH and by noxious heat stimuli. It is also sensitized by a number of inflammatory mediators and thus appears to be a polymodal integrator of painful stimuli.

The prototypical VR1 antagonist is capsazepine (Walpole *et al.*, *J. Med. Chem.*, 37:1942, 1994) – VR1 IC₅₀ of 420nM. A novel series of sub-micromolar antagonists has also been reported recently (Lee *et al.*, *Bioorg. Med. Chem.*, 9:1713, 2001), but these reports provide no evidence for *in vivo* efficacy. A much higher affinity antagonist has been derived from the ‘ultra-potent’ agonist resiniferatoxin. Iodo-resiniferatoxin (Wahl *et al.*, *Mol. Pharmacol.*, 59:9, 2001) is a nanomolar antagonist of VR1 but does not possess properties suitable for an oral pharmaceutical. This last is also true of the micromolar peptoid antagonists described by Garcia-Martinez (*Proc. Natl. Acad. Sci., USA*, 99:2374, 2002).

WO-A-0208221 (Neurogen Corporation *et al.*) discloses structurally related VR1 antagonists based around a piperazine core.

We herein describe another novel series of VR1 modulators. These comprise predominantly VR1 antagonists but encompass VR1 partial antagonists and VR1 partial agonists. Such compounds have been shown to be efficacious in animal models of pain.

The present invention provides compounds of formula I:



(I)

10

wherein:

A^1 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

15 A^1 is unsubstituted or substituted by one, two or three substituents independently chosen from halogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, hydroxy, cyano, nitro and amino;

20 A^2 is phenyl, a six-membered aromatic heterocycle containing one, two or three nitrogen atoms, or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

A^2 is unsubstituted or substituted by one, two or three groups independently chosen from halogen, cyano, nitro, amino, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{1-6} alkyl C_{2-6} alkenyl, C_{2-6} alkynyl, halo C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo C_{1-6} alkyl, thiol, SF_5 , phenyl C_{1-6} alkyl and phenyl;

25 L is a bond or C_{1-6} alkylene;

R^1 and R^2 independently chosen from hydrogen and C_{1-6} alkyl;

or R^1 and R^2 may, together, form a methylene or ethylene bridge;

W is halogen, C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy or halo C_{1-6} alkoxy;

X is O, S or NR³ where R³ is hydrogen, hydroxy, C₁₋₆alkoxy, C₁₋₆alkyl, cyano, C₃₋₆cycloalkyl, a six-membered saturated heterocycle containing one or two heteroatoms independently chosen from O, N and S, and R³ is, if possible, optionally substituted by C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, halogen, amino, nitro, hydroxy, phenyl, a six-membered aromatic heterocycle containing up to three nitrogen atoms or a five-membered aromatic heterocycle containing up to four heteroatoms chosen from O, N and S, at most one heteroatom being O or S;

or X, together with the atom to which it is attached, and Y, form an unsaturated five-membered ring together with A²;

Y is a bond, C₁₋₄alkylene, NH or NH(CH₂)₁₋₃;

or a pharmaceutically acceptable salt thereof.

A¹ is preferably phenyl or a nitrogen containing heterocycle which is unsubstituted or substituted with one or two groups independently chosen from halogen, hydroxy, cyano, nitro, amino, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₆alkoxy and haloC₁₋₄alkoxy. More particularly A¹ is phenyl, pyridinyl, pyrimidinyl or imidazolyl. Preferred substituents are halogen, C₁₋₄alkyl, C₁₋₄alkoxy and haloC₁₋₄alkyl, such as fluorine, chlorine, methyl, methoxy and trifluoromethyl.

Particular embodiments of A¹ include 3-methylpyrid-2-yl, pyrid-2-yl, 1-methylimidazol-2-yl, 3-chloropyrid-2-yl, 3-fluoropyrid-2-yl, 3-methoxypyrid-2-yl, phenyl, pyrimidin-2-yl and 3-trifluoromethylpyrid-2-yl. Pyridyl, particularly pyrid-2-yl, especially substituted at the 3- position, preferably by methyl, is preferred.

A² is preferably a six-membered aromatic or heteroaromatic ring. A² is preferably monosubstituted, particularly *para* to the point of attachment to Y. The substituent is preferably haloC₁₋₆alkyl, C₁₋₆alkyl, SF₅, phenyl, phenylC₁₋₆alkyl, haloC₁₋₆alkoxy, cyano or di(C₁₋₆alkyl)amino. More preferably the substituent is haloC₁₋₄alkyl, C₁₋₄alkyl, SF₅, phenyl, phenylC₁₋₂alkyl, haloC₁₋₄alkoxy, cyano or di(C₁₋₄alkyl)amino. Particular substituents include trifluoromethyl, isopropyl, 1,2,2,2-tetrafluoro-1-trifluoromethylethyl, tert-butyl, SF₅, n-butyl, benzyl, phenyl, 2,2,2-trifluoroethyl, trifluoromethoxy, cyano and dimethylamino.

A² is preferably phenyl or pyridyl, particularly phenyl.

Particular embodiments of A² include 4-trifluoromethylphenyl, 4-isopropylphenyl, 4-(1,2,2,2-tetrafluoro-1-trifluoromethylethyl)phenyl, 4-benzylphenyl, 4-(pentafluoro- λ^6 -sulfonyl)phenyl, biphenyl, 3-trifluoromethylpyrid-6-yl, 4-(2,2,2-trifluoroethyl)phenyl, 4-trifluoromethoxyphenyl, 4-cyanophenyl and 4-dimethylaminophenyl. One

embodiment is 4-trifluoromethylphenyl.

L is preferably a bond or C₁₋₃alkylene, such as ethylene. Most preferably L is a bond.

R¹ and R² are preferably independently hydrogen, C₁₋₂alkyl or together form a methylene or ethylene bridge. More preferably they are hydrogen, methyl or an ethylene bridge. In one embodiment both are hydrogen.

W is preferably halogen, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy or haloC₁₋₄alkoxy. More preferably W is halogen, C₁₋₂alkoxy or haloC₁₋₂alkyl. Particular embodiments of W include fluorine, methoxy and fluoromethyl.

X is preferably O, S, or NR³ where R³ is hydrogen, hydroxy, C₁₋₆alkyl, C₁₋₆alkoxy, C₃₋₆cycloalkyl, piperidiny, piperazinyl or morpholinyl optionally substituted, if possible, by C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, phenyl or pyridyl. More preferably X is O, S or NR³ where R³ is cyano or 1-phenylpiperidin-4-yl. X may be O.

Y is preferably a bond, NH, NHCH₂, CH₂ or CH₂CH₂.

X, the atom to which X is attached, Y and A² may together form an imidazole.

Particular embodiments of the invention include:

- 4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;
- 4-fluoro-4(pyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;
- 4-fluoro-4(pyridine-2-yl)-N-[4-trifluoromethylbenzyl]piperidine-1-carboxamide;
- 2-{4-fluoro-1-[4-trifluoromethylbenzoyl]piperidin-4-yl}pyridine;
- 2-(4-fluoro-1-{[4-trifluoromethylphenyl]acetyl}piperidin-4-yl)pyridine;
- 2-(4-fluoro-1-{3-[4-trifluoromethylphenyl]propanoyl}piperidin-4-yl)pyridine
- 4-fluoro-4-(1-methyl-1H-imidazol-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;
- 4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide;
- 4-methoxy-4-pyridin-2-yl-N-[4-trifluoromethylbenzyl]piperidine-1-carboxamide;

- 4-fluoro-*N*-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-*N*{4-[1,2,2,2-tetrafluoro-1-trifluoromethylethyl]
 phenyl}piperidine-1-carboxamide;
N-(4-*Tert*-butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-
 5 carboxamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-*N*[4-(pentafluoro- λ^6 -sulfanyl)phenyl]piperidine-
 1-carboxamide;
N-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
N-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 10 *N*-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-*N*[5-trifluoromethylpyridin-2-yl]piperidine-1-
 carboxamide;
 4-(3-chloropyridin-2-yl)-4-fluoro-*N*[4-trifluoromethylphenyl]piperidine-1-
 carboxamide
 15 4-fluoro-4-(3-fluoropyridin-2-yl)-*N*[4-trifluoromethylphenyl]piperidine-1-
 carboxamide;
 4-fluoro-4-(3-methoxypyridin-2-yl)-*N*[4-trifluoromethylphenyl]piperidine-1-
 carboxamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-*N*[4-trifluoromethylphenyl]piperidine-1-
 20 carbothioamide;
N-cyano-4-fluoro-4-(3-methylpyridin-2-yl)-*N*[4-trifluoromethylphenyl]piperidine-
 1-carboximidamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(1-phenylpiperidin-4-yl)-*N*[4-
 trifluoromethylphenyl]piperidine-1-carboximidamide;
 25 4-fluoro-4-phenyl-*N*[4-trifluoromethylphenyl]piperidine-1-carboxamide;
 (+/-)-(syn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-*N*[4-
 trifluoromethylphenyl]piperidine-1-carboxamide;
 4-(fluoromethyl)-4-pyridin-2-yl-*N*[4-trifluoromethylphenyl]piperidine-1-
 carboxamide;
 30 *syn* and *anti*-3-fluoro-3-pyridin-2-yl-*N*[4-trifluoromethylphenyl]-8-
 azabicyclo[3.2.1]octane-8-carboxamide & 3-fluoro-3-pyridin-2-yl-*N*[4-
 trifluoromethylphenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide;
 4-fluoro-4-pyrimidin-2-yl-*N*[4-trifluoromethylphenyl]piperidine-1-carboxamide;
 4-fluoro-4-(3-phenylpropyl)-*N*[4-trifluoromethylphenyl]piperidine-1-carboxamide;

2-[4-fluoro-4-(3-methylpyridin-2-yl)piperidin-1-yl]-6-trifluoromethyl-1*H*-benzimidazole;
 2-(4-fluoro-4-pyridin-2-ylpiperidin-1-yl)-6-(trifluoromethyl)-1*H*-benzimidazole;
 4-fluoro-N-[4-trifluoromethylphenyl]-4-[3-trifluoromethylpyridin-2-yl]piperidine-
 5 1-carboxamide;
 4-fluoro-N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 4-fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethoxyphenyl]piperidine-1-
 10 carboxamide;
 N-(4-cyanophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide;
 N-[4-dimethylaminophenyl]-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-
 carboxamide;
 or a pharmaceutically acceptable salt thereof.

15 As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. "Alkylthio" shall be construed in an analogous
 20 manner.

As used herein, the terms "haloC₁₋₆alkyl" and "haloC₁₋₆alkoxy" means a C₁₋₆alkyl or C₁₋₆alkoxy group in which one or more (in particular, 1 to 3) hydrogen atoms have been replaced by halogen atoms, especially fluorine or chlorine atoms. Preferred are fluoroC₁₋₆alkyl and fluoroC₁₋₆alkoxy groups, in particular,
 25 fluoroC₁₋₃alkyl and fluoroC₁₋₃alkoxy groups, for example, CF₃, CH₂CH₂F, CH₂CHF₂, CH₂CF₃, OCF₃, OCH₂CH₂F, OCH₂CHF₂ or OCH₂CF₃, and most especially CF₃ and OCF₃.

As used herein, the terms "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable
 30 alkenyl groups include vinyl and allyl. A suitable alkynyl group is acetylene or propargyl.

When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine. The most preferred halogens are fluorine and chlorine, especially fluorine.

Examples of 6-membered heterocycles are pyridine, pyrimidine, pyrazine, pyridazine and triazine.

Examples of 5-membered heterocycles are thiophene, furan, pyrrole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-
5 triazole, oxadiazole, thiadiazole and tetrazole.

In a further aspect of the present invention, the compounds of formula I may be prepared in the form of a pharmaceutically acceptable salt, especially an acid addition salt.

For use in medicine, the salts of the compounds of formula I will be
10 non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound
15 according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulphuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic
20 group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

25 The salts may be formed by conventional means, such as by reacting the free base form of the compound of formula I with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion
30 exchange resin.

The present invention also includes within its scope N-oxides of the compounds of formula I above. In general, such N-oxides may be formed on any available nitrogen atom. The N-oxides may be formed by conventional means,

such as reacting the compound of formula I with oxone in the presence of wet alumina.

The present invention includes within its scope prodrugs of the compounds of formula I above. In general, such prodrugs will be functional derivatives of the compounds of formula I which are readily convertible *in vivo* into the required compound of formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula I and salts thereof, for example, hydrates.

The compounds according to the invention may have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, the compounds of formula I may also exist in tautomeric forms and the invention includes within its scope both mixtures and separate individual tautomers.

The compounds may exist in different isomeric forms such as *syn* and *anti*-isomers, all of which are encompassed by the present invention.

The present invention further provides pharmaceutical compositions comprising one or more compounds of formula I in association with a pharmaceutically acceptable carrier or excipient.

Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, auto-injector devices, suppositories, creams or gels; for oral, parenteral, intrathecal, intranasal, sublingual, rectal or topical administration, or for administration by inhalation or insufflation. Oral compositions such as tablets, pills, capsules or

wafers are particularly preferred. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid pre-formulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these pre-formulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid pre-formulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Favoured unit dosage forms contain from 1 to 500 mg, for example 1, 5, 10, 25, 50, 100, 300 or 500 mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

In the treatment of painful conditions such as those listed below, a suitable dosage level is about 1.0 mg to 15 g per day, preferably about 5.0 mg to

1 g per day, more preferably about 5 mg to 500 mg per day, especially 10 mg to 100 mg per day. The compounds may be administered on a regimen of 1 to 4 times per day.

5 It will be appreciated that the amount of a compound of formula I required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.

10 The invention further provides a compound of formula I as defined above, or a pharmaceutically acceptable salt thereof, for use in treatment of the human or animal body. Preferably, said treatment is for a condition which is susceptible to treatment by modulation (preferably antagonism) of VR1 receptors.

15 The compounds of the present invention will be of use in the prevention or treatment of diseases and conditions in which pain and/or inflammation predominates, including chronic and acute pain conditions. Such conditions include rheumatoid arthritis; osteoarthritis; post-surgical pain; musculo-skeletal pain, particularly after trauma; spinal pain; myofascial pain syndromes; headache, including migraine, acute or chronic tension headache, cluster headache, temporomandibular pain, and maxillary sinus pain; ear pain; 20 episiotomy pain; burns, and especially primary hyperalgesia associated therewith; deep and visceral pain, such as heart pain, muscle pain, eye pain, orofacial pain, for example, odontalgia, abdominal pain, gynaecological pain, for example, dysmenorrhoea, pain associated with cystitis and labour pain, chronic pelvic pain, chronic prostatitis and endometriosis; pain associated with nerve and 25 root damage, such as pain associated with peripheral nerve disorders, for example, nerve entrapment and brachial plexus avulsions, amputation, peripheral neuropathies, tic douloureux, atypical facial pain, nerve root damage, and arachnoiditis; itching conditions including pruritis, itch due to hemodialysis, and contact dermatitis; pain (as well as broncho-constriction and inflammation) 30 due to exposure (e.g. via ingestion, inhalation, or eye contact) of mucous membranes to capsaicin and related irritants such as tear gas, hot peppers or pepper spray; neuropathic pain conditions such as diabetic neuropathy, chemotherapy-induced neuropathy and post-herpetic neuralgia; "non-painful" neuropathies; complex regional pain syndromes; pain associated with carcinoma,

often referred to as cancer pain; central nervous system pain, such as pain due to spinal cord or brain stem damage, low back pain, sciatica and ankylosing spondylitis; gout; scar pain; irritable bowel syndrome; inflammatory bowel disease; urinary incontinence including bladder detrusor hyper-reflexia and
5 bladder hypersensitivity; respiratory diseases including chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, asthma and rhinitis, including allergic rhinitis such as seasonal and perennial rhinitis, and non-allergic rhinitis; autoimmune diseases; and immunodeficiency disorders.

Thus, according to a further aspect, the present invention provides a
10 compound of formula I for use in the manufacture of a medicament for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1 activity.

The present invention also provides a method for the treatment or prevention of physiological disorders that may be ameliorated by modulating VR1
15 activity, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I.

According to a further or alternative aspect, the present invention provides a compound of formula I for use in the manufacture of a medicament for
20 the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

The present invention also provides a method for the treatment or prevention of a disease or condition in which pain and/or inflammation predominates, which method comprises administration to a patient in need
25 thereof of an effective amount of a compound of formula I or a composition comprising a compound of formula I.

According to a further aspect of the present invention, it may be desirable to treat any of the aforementioned conditions with a combination of a compound according to the present invention and one or more other pharmacologically
30 active agents suitable for the treatment of the specific condition. The compound of formula I and the other pharmacologically active agent(s) may be administered to a patient simultaneously, sequentially or in combination.

Thus, for example, for the treatment or prevention of pain and/or inflammation, a compound of the present invention may be used in conjunction with other

analgesics, such as acetaminophen (paracetamol), aspirin and other NSAIDs, including selective cyclooxygenase-2 (COX-2) inhibitors, as well as opioid analgesics, especially morphine, NR2B antagonists, bradykinin antagonists, anti-migraine agents, anticonvulsants such as oxcarbazepine and carbamazepine, 5 antidepressants (such as TCAs, SSRIs, SNRIs, substance P antagonists, etc.), spinal blocks, gabapentin, pregabalin and asthma treatments (such as β_2 -adrenergic receptor agonists or leukotriene D₄ antagonists (e.g. montelukast).



Specific anti-inflammatory agents include diclofenac, ibuprofen, indomethacin, nabumetone, ketoprofen, naproxen, piroxicam and sulindac, 10 etodolac, meloxicam, rofecoxib, celecoxib, etoricoxib, parecoxib, valdecoxib and tilcoxib. Suitable opioid analgesics of use in conjunction with a compound of the present invention include morphine, codeine, dihydrocodeine, diacetylmorphine, hydrocodone, hydromorphone, levorphanol, oxymorphone, alfentanil, buprenorphine, butorphanol, fentanyl, sufentanyl, meperidine, methadone, 15 nalbuphine, propoxyphene and pentazocine; or a pharmaceutically acceptable salt thereof. Suitable anti-migraine agents of use in conjunction with a compound of the present invention include CGRP-antagonists, ergotamines or 5-HT₁ agonists, especially sumatriptan, naratriptan, zolmatriptan or rizatriptan.

Therefore, in a further aspect of the present invention, there is provided a 20 pharmaceutical composition comprising a compound of the present invention and an analgesic, together with at least one pharmaceutically acceptable carrier or excipient.

In a further or alternative aspect of the present invention, there is provided a product comprising a compound of the present invention and an 25 analgesic as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a disease or condition in which pain and/or inflammation predominates.

The compounds of formula I in which Y is NH or NH(CH₂)₁₋₃ can be made by reacting a compound of formula II with a compound of formula III:

30



wherein X^1 is O or S, P is H or a C_{1-6} alkoxycarbonyl group such as tert-butoxycarbonyl and A^1 , A^2 , L, R^1 , R^2 and W are as defined above.


The reaction is generally carried out in a solvent such as dichloromethane in the presence of a base such as triethylamine at about room temperature for about one hour.

The resulting product can be converted into a compound of formula I in which X is NR^3 by reacting with a compound of formula VIII:



in which R^3 is as defined above, in the presence of a catalyst such as silver acetate in a solvent such as acetonitrile at about $140^\circ C$ for about 10 minutes in a microwave or for several hours at reflux.

The compound of formula II in which W is OH can be made by reacting a compound of formula VI with a compound of formula VII:





20 wherein A^1 , R^1 , R^2 and P are as defined above and L^1 is a leaving group such as H or Br. The compound of formula VI is first converted to its anion by reacting with a strong base such as N-butyl lithium in hexanes and then reacted with the

compound of formula VII generally in a solvent such as THF between -78°C and room temperature for several hours.

The resulting group W can be converted into other groups W by standard methods known in the art. For example a hydroxy group can be converted to a
 5 fluorine atom by reacting with diethylaminosulphur trifluoride in a solvent such as dichloromethane at a temperature between -78°C and room temperature for about two hours. A hydroxy group can be converted to an alkoxy group by reacting first with a strong base such as sodium hydride in a solvent such as a mixture of tetrahydrofuran and dimethyl formamide for about two hours followed
 10 by addition of the appropriate alkyl iodide and leaving to react for about 3 days.

Compounds of formula II in which W is CN can also be made by reacting a compound of formula X with a compound of formula XI:




15 wherein A¹ and R are as defined above in the presence of a strong base such as sodium hydride in a solvent such as anhydrous dimethylformamide at about 60°C for about 5½ hours.

The cyano group can be converted to an ester using hydrogen chloride gas in anhydrous methanol. This can be reduced to a hydroxymethyl group using a
 20 reagent such as lithium aluminium hydride in a solvent such as tetrahydrofuran at about -30°C for about one hour. This group can be converted to a fluoromethyl group using a reagent such as diethylaminosulphur trifluoride in a solvent such as anhydrous ethyl acetate at between -78°C and room temperature for several hours.

25 Compounds of formula III in which X¹ is O can be made by reacting the corresponding amine with triphosgene followed by a base such as triethylamine in a solvent such as dichloromethane for about one hour.

Compounds of formula III in which X¹ is O can be made by reacting the corresponding carboxylic acid with an azide such as diphenyl phosphoryl azide in
 30 the presence of a base such as triethylamine at about 90°C for about 3 hours so that a Curtius rearrangement occurs.

Compounds of formula VII can be made by hydrogenating a compound of formula IX:




5

wherein R^1 , R^2 and P are as defined above by stirring with a reducing agent such as zinc powder in a solvent such as acetic acid at reflux for about 18 hours.

In an alternative process, compounds of formula I in which Y is a bond or C_{1-4} alkylene can be made by reacting a compound of formula II with a compound of formula IV:

10




wherein both X^1 s are O or S, Y is a bond or C_{1-4} alkylene and A^2 is as defined above. The reaction is generally carried out in a solvent such as tetrahydrofuran at about 70°C for several hours. The compound of formula IV may be pre-reacted with an activating agent such as carbonyldiimidazole in a solvent such as tetrahydrofuran for about 3 hours at about 70°C.

15

In a further process, compounds of formula I in which X, together with the atom to which it is attached, and Y, form an unsaturated five membered ring together with A^2 can be made by reacting a compound of formula II with a compound of formula V:

20



wherein X, together with the atom to which it is attached and Y, form an unsaturated five membered ring together with A². The reaction is generally carried out in a solvent such as ethanol with heating to about 160°C for about 10 minutes preferably in a microwave.

Where the synthesis of intermediates and starting materials is not described these compounds are commercially available or can be made from commercially available compounds by standard methods.

During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The following Examples serve to illustrate the preparation of compounds of the present invention.

COMMON INTERMEDIATES

Description Example 1 *Tert*-butyl 4-hydroxy-4-(3-methylpyridin-2-yl)piperidine-1-carboxylate

N-butyl lithium (15.63ml, 1.6M in hexanes) was added dropwise to a stirred solution of 2-bromo-3-methyl pyridine (4.3g, 25mmol) in THF (35ml) at -78°C over 40 minutes. The anion formed went from orange to brown. After 30 minutes at -78°C, 1-*tert*butoxycarbonyl-4-piperidone (5g) in THF (30ml) was added dropwise over 20 minutes. The reaction mixture was allowed to warm to room temperature overnight. Water (50ml) was added and the organic layer was separated. The aqueous was extracted using ethyl acetate (2x50ml). The organics

were combined, dried (Na₂SO₄) and evaporated. Purification by column chromatography on silica using 5-10% ethyl acetate in isohexane yielded the desired product (1.72g).

1H NMR δ (ppm) 400MHz (CDCl₃): 1.44 (2 H, d, J = 12.9Hz), 1.50 (9 H, s), 2.27-2.34 (2 H, m), 2.50 (3 H, s), 3.26-3.4 (2 H, br m), 4.0-4.2 (2 H, br m), 6.63 (1 H, s), 7.18 (1 H, dd, J = 4.7, 7.8Hz), 7.50(1H, dd, J=1.2, 7.8Hz), 8.38 (1 H, dd, J = 1.2, 4.7Hz). MSp m/z for MH⁺ =293.

10 Description Example 2 Tert-butyl 4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxylate

Description Example 1 (4.47g, 15mmol) in dichloromethane (150ml) was cooled to -78°C and excess diethylaminosulphur trifluoride (11.15g, 69mmol) in dichloromethane (50ml) was added dropwise to the stirred solution. The reaction was warmed to room temperature over 2 hours. Water (50ml) was added and the organic layer separated. The aqueous was extracted with dichloromethane (2x50ml). The organics were combined, dried (Na₂SO₄) and evaporated. Purification by column chromatography on silica using 10-100% ethyl acetate in isohexane yielded the desired product (2.65g).

1H NMR δ (ppm) 400MHz(CDCl₃): 1.48 (9 H, s), 1.95-2.1 (2H, br m) 2.15-2.45 (2H, br m) 2.50 (3 H, d, J = 5.9Hz), 3.15-3.3 (2 H, br m), 4.0-4.2 (2 H, br m), 7.12 (1 H, dd, J = 4.7, 7.8Hz), 7.46 (1 H, dd, J = 1.2, 6.7Hz), 8.35 (1 H, d, J = 4.7Hz). MSp m/z for MH⁺ =295.

25 Description Example 3 2-(4-Fluoropiperidin-4-yl)-3-methylpyridine

Description Example 2 (1.44g, 4.9mmol) in dichloromethane (20ml) was treated with trifluoroacetic acid (5ml) and stirred at room temperature for 3 hours. The reaction mixture was evaporated and purified using a strong cation exchange cartridge to give the desired product (710mg).

1H NMR δ (ppm) 400MHz(CDCl₃): 2.01-2.08 (2 H, m), 2.17-2.35 (2 H, m), 2.50 (3 H, d, J = 5.5Hz), 3.04 - 3.11 (4 H, m), 7.11 (1 H, dd, J = 4.7, 7.4Hz), 7.45 (1 H, dd, J = 7.4, 0.8Hz), 8.37 (1 H, d, J = 4.7Hz). MSp m/z for MH⁺ =195.

30 Description Example 4 2-(4-Fluoropiperidin-4-yl)pyridine

The title compound was prepared in analogous fashion to Description Example 3.

¹H NMR δ (ppm) 400MHz (CDCl₃): 1.84-1.91 (2 H, m), 2.14-2.22 (1 H, m), 2.24-2.32 (1 H, m), 3.04-3.10 (4 H, m), 7.18-7.22 (1 H, m), 7.56 (1 H, dd, $J = 1.2, 7.8$ Hz), 7.70-7.74 (1 H, m), 8.56 (1 H, m). MS m/z for MH⁺ = 181.

5 Description Example 5 *Tert* butyl 4-hydroxy-4-(1-methyl-1*H*-imidazol-2-yl)piperidine-1-carboxylate

N-butyl lithium (6.25ml, 1.6M in hexanes) was added dropwise to a solution of 1-methylimidazole in THF (15ml) at -78°C. After 30 minutes at this temperature, 1-tert-butoxycarbonyl-4-piperidone (2g) in THF (15ml) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight. Water (50ml) was added and the organics were separated. The aqueous was extracted using ethyl acetate (2x50ml). The organics were combined, dried (Na₂SO₄) and evaporated. Purification by column chromatography on silica using 5% methanol in dichloromethane as the eluant gave the desired product (2g).

15 ¹H NMR δ (ppm) 400MHz (CDCl₃): 1.46 (9 H, s), 1.77-1.85 (2 H, m), 2.05-2.18 (2 H, br m), 3.18 (1 H, br s), 3.26-3.37 (2 H, br m), 3.8-3.93 (2H, br m), 3.84 (3H, s), 6.81 (2 H, s). MS m/z for MH⁺ = 282.

20 Description Example 6 *Tert* butyl 4-methoxy-4-(pyridin-2-yl)piperidine-1-carboxylate

Description Example 1 (557mg, 2mmol) in THF (5ml) was treated with sodium hydride (56mg, 95% dry, 2.2mmol) and stirred at room temperature for 20 minutes. Dimethylformamide (5ml) was added to aid solubility of the anion formed. Iodomethane (131 μ l) was added. After 2 hours and 4 hours, further iodomethane (50 μ l) was added. The reaction was stirred for 72 hours. Water (20ml) was added and the aqueous was extracted using ethyl acetate (3 x 20ml). The combined organics were dried (Na₂SO₄), filtered and evaporated. The compound was purified by column chromatography using 20% ethyl acetate in isohexane as eluant to give the desired material (250mg). ¹H NMR δ (ppm)

30 400MHz (CDCl₃): 1.46 (9 H, s), 1.95-1.99 (2 H, m), 2.05-2.12 (2 H, m), 3.06 (3 H, s), 3.18-3.24 (2 H, m), 3.92-3.95 (2 H, m), 7.20 (1 H, dd, $J = 1.2, 12.1$ Hz), 7.48-7.50 (1 H, m), 7.69-7.73 (1 H, m), 8.57-8.59 (1 H, m).

FINAL PRODUCTS

Example 1 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

5 Trifluoroacetic acid (2ml) was added to a stirred solution of Description Example 2 (510mg, 1.73mmol) in dichloromethane (8ml). After 1 hour, the reaction was complete and the solvent was removed by evaporation. The residue was dissolved in dichloromethane (10ml), treated with triethylamine (1.25ml) followed by 4-trifluoromethylphenyl isocyanate (324mg, 1.73mmol) and stirred at room
10 temperature for 1 hour. The reaction mixture was evaporated and purified by column chromatography on silica using 20-33% ethyl acetate in isohexane to give the desired product (470mg).

¹H NMR δ (ppm) (CDCl₃): 2.13-2.20 (2 H, m), 2.37-2.49 (2 H, m), 2.52 (3 H, d, J = 5.9Hz), 3.38-3.48 (2 H, m), 4.04-4.11 (2 H, m), 6.57 (1 H, s), 7.15 (1 H, dd, J = 4.7, 7.8Hz), 7.48-7.56 (5 H, m), 8.35 (1 H, d, J = 4.7Hz). MS_{sp} m/z for MH⁺ = 382.

Example 2 4-Fluoro-4(pyridin-2-yl)N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

Using Description Example 4 and the procedure shown in Example 1, the title
20 compound was obtained.

¹H NMR δ (ppm) 400MHz(CDCl₃): 1.96-2.04 (2 H, m), 2.32-2.50 (2 H, m), 3.37-3.44 (2 H, m), 4.09-4.13 (2 H, m), 6.57 (1 H, s), 7.22-7.25 (1 H, m), 7.48-7.60 (5 H, m), 7.73-7.78 (1 H, m), 8.54-8.56 (1 H, m). MS_{sp} m/z for MH⁺ = 368.

25 Example 3 4-Fluoro-4(pyridine-2-yl)N-[4-trifluoromethylbenzyl]piperidine-1-carboxamide

Using Description Example 4, (4-trifluoromethylbenzyl)isocyanate and the procedure shown in Example 1, the title compound was obtained.

30 ¹H NMR δ (ppm) 400MHz (DMSO): 1.81-1.89 (2 H, m), 2.05-2.23 (2 H, m), 3.06-3.14 (2 H, m), 4.00-4.06 (2 H, m), 4.35 (2 H, d, J = 5.9Hz), 7.31-7.38 (2 H, m), 7.49 (2 H, d, J = 7.8Hz), 7.59 (1 H, dd, J = 1.2, 7.8Hz), 7.68 (2 H, d, J=7.8Hz), 7.86-7.90 (1 H, m), 8.56-8.58 (1 H, m). MS_{sp} m/z for MH⁺ = 382.

Example 4 2-{4-Fluoro-1-[4-trifluoromethylbenzoyl]piperidin-4-yl}pyridine

4-trifluoromethylbenzoic acid (38mg, 0.2mmol) in THF (1ml) was treated with 1,1'-carbonyldiimidazole (32mg, 0.2mmol) and heated at 70 °C for 3 hours.

Description Example 4 in THF (1ml) was added and the reaction mixture was
5 heated at 70 °C overnight. Following evaporation, the compound was purified by column chromatography on silica using 33% ethyl acetate in isohexane as the eluant gave the desired product (25mg).

¹H NMR δ (ppm) 400MHz (CDCl₃) 1.8-2.1 (2 H, m), 2.25-2.51 (2 H, m), 3.20-3.35 (1 H, m), 3.34-3.59 (1H, br m), 3.61-3.76 (1H, br m), 4.71-4.85 (1 H, br m),
10 7.24-7.27 (1 H, m), 7.57-7.61 (3 H, m), 7.70 (2 H, d, J=7.8Hz), 7.74-7.79 (1 H, m), 8.57-8.59 (1 H, m). MS_{sp} m/z for MH⁺ =353.

Example 5 2-(4-Fluoro-1-{[4-trifluoromethylphenyl]acetyl}piperidin-4-yl)pyridine

15 Using Description Example 4, 4-trifluoromethylphenyl acetic acid and the procedure shown in Example 4, the title compound was obtained.

¹H NMR δ (ppm) 500MHz (CDCl₃) 1.86-2.0 (2 H, m), 2.13-2.33 (2 H, m), 3.03-3.09 (1 H, m), 3.46-3.52 (1 H, m), 3.83 (2 H, d, J = 4.2Hz), 3.85-3.89 (1 H, m), 4.65-4.72 (1H, m), 7.21-7.23 (1 H, m), 7.40 (2 H, d, J = 8.1Hz), 7.55 (1 H, d, J = 7.8Hz), 7.60
20 (2 H, d, J = 8.1Hz), 7.71-7.77 (1 H, m), 8.53 (1 H, d, J = 4.9Hz). MS_{sp} m/z for MH⁺ =367.

Example 6 2-(4-Fluoro-1-{3-[4-trifluoromethylphenyl]propanoyl}piperidin-4-yl)pyridine

25 Using Description Example 4, 4-trifluoromethylhydrocinnamic acid and the procedure shown in Example 4, the title compound was obtained.

¹H NMR δ (ppm) 360MHz (CDCl₃): 1.88-1.96 (2 H, m), 2.12-2.33 (2 H, m), 2.69 (2 H, t, J = 7.7Hz), 2.98-3.09 (3 H, m), 3.41-3.49 (1 H, m), 3.79-3.84 (1 H, m), 4.66-4.71 (1 H, m), 7.21-7.24 (1 H, m), 7.36 (2 H, d, J = 8.1Hz), 7.55 (3 H, d, J = 8.1Hz),
30 7.71-7.76 (1 H, m), 8.54 (1 H, d, J = 3.9Hz). MS_{sp} m/z for MH⁺ =381.

Example 7 4-Fluoro-4-(1-methyl-1*H*-imidazol-2-yl)-*N*-[4-trifluoromethylphenyl]piperidine-1-carboxamide

The title compound was prepared in analogous fashion to Example 1 from Description Example 5.

- 5 ¹H NMR δ (ppm) 400MHz (DMSO): 2.10-2.27 (4 H, m), 3.29-3.37 (2 H, m), 3.77 (3 H, d, J = 2.0Hz), 3.94-4.00 (2 H, m), 6.83 (1 H, s), 7.17 (1 H, s), 7.59 (2 H, d J=8.6Hz), 7.69 (1 H, d J=8.6Hz), 9.01 (1 H, s). MSp m/z for MH⁺ =371.

10 Example 8 4-methoxy-4-pyridin-2-yl-*N*-[4-trifluoromethylphenyl]piperidine-1-carboxamide

- Description Example 6 (250mg, 0.86mmol) in dichloromethane (4ml) was treated with trifluoroacetic acid (1ml) and stirred at room temperature overnight. The reaction mixture was evaporated, and the amine was isolated using a strong cation exchange cartridge as the free base (186mg). This amine (83mg) in
- 15 dichloromethane (1ml) was treated with 4-trifluoromethylphenylisocyanate (62ul, 0.43mmol) and stirred at room temperature for 1 hour. Following evaporation the compound was purified by column chromatography on silica using 50% ethyl acetate in isohexane as the eluant to give the desired compound (144mg).

- 20 ¹H NMR δ (ppm) 360MHz (CDCl₃): 2.04 -2.25 (4 H, m), 3.10 (3 H, s), 3.38-3.46 (2 H, m), 3.93 (2 H, m), 6.54 (1 H, s), 7.22 (1 H, dd, J = 5.1, 7.2Hz), 7.53 (5 H, m), 7.71-7.76 (1 H, m), 8.58 (1 H, dd, J = 0.7, 4.2Hz). MSp m/z for MH⁺ =380.

Example 9 4-Methoxy-4-pyridin-2-yl-*N*-[4-trifluoromethylbenzyl]piperidine-1-carboxamide

- 25 The title compound was obtained using the procedure shown in Example 8 and employing Description Example 6 and [4-trifluoromethylbenzyl]isocyanate.
- 30 ¹H NMR δ (ppm) 360MHz (CDCl₃): 2.02 -2.18 (4 H, m), 3.07 (3 H, s), 3.28-3.36 (2 H, m), 3.79-3.83 (2 H, m), 4.50 (2 H, d, J = 5.6Hz), 4.84-4.87 (1 H, m), 7.18-7.22 (1 H, m), 7.43 (2 H, J=8.1Hz) 7.49 (1H, J=8Hz), 7.58 (2 H, J=8.1Hz), 7.69-7.74 (1 H, m), 8.58 (1 H, dd, J = 1.1, 4.2Hz). MSp m/z for MH⁺ =394.

Example 10 4-Fluoro-*N*-(4-isopropylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

4-isopropylphenylisocyanate (40.3mg, 0.25mmol) in dichloromethane (1ml) was treated with Description Example 3 (48.5mg, 0.25mmol) in dichloromethane (1ml) and stirred overnight at room temperature. The compound was purified by column chromatography on silica using 20-40% ethyl acetate in isohexane the eluant to give the desired compound (75mg).

¹H NMR δ (ppm) 400MHz (CDCl₃): 1.23 (6 H, d, J = 6.7Hz), 2.10-2.17 (2 H, m), 2.35-2.52 (5 H, m), 2.83-2.90 (1 H, m), 3.37-3.44 (2 H, m), 4.02-4.06 (2 H, m), 6.35 (1 H, s), 7.12-7.16 (3 H m), 7.26 (2 H, d, J=6.8Hz), 7.28 (1 H, s), 7.48 (1 H, dd, J = 0.8, 7.0Hz), 8.35 (1 H, d, J = 4.7Hz). MS_{sp} m/z for MH⁺ =356.

Example 11 4-Fluoro-4-(3-methylpyridin-2-yl)-*N*{4-[1,2,2,2-tetrafluoro-1-trifluoromethylethyl]phenyl}piperidine-1-carboxamide

4-(1,2,2,2-tetrafluoro-1-trifluoromethylethyl)phenylamine (131mg, 0.5mmol) in dichloromethane (5ml) was treated with triphosgene (49mg, 0.167mmol) followed by triethylamine (50.5mg,0.5mmol).After one hour Description Example 3 (97mg, 0.5mmol) in dichloromethane (1ml) was added and the reaction mixture was stirred at room temperature overnight. Water (2ml) was added and the organics were separated using a phase separation cartridge. The compound was purified using a strong cation exchange cartridge followed by column chromatography on silica using 20% ethyl acetate in hexane as the eluant to give the desired compound (15mg).

¹H NMR δ (ppm) 400MHz (CDCl₃): 2.12-2.2 (2 H, m), 2.37-2.54 (5 H, m)3.42-3.49 (2 H, m), 4.03-4.1 (2 H, m), 6.57 (1 H, s), 7.15 (1 H, dd, J = 4.5, 7.6Hz), 7.49 - 7.52 (5H, m). 8.35 (1 H, d, J = 4.7Hz). MS_{sp} m/z for MH⁺ =482.

Example 12 *N*-(4-*Tert*butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

The title compound was obtained using the procedure shown in Example 10 using 4-*tert*-butylphenyl isocyanate and Description Example 3.

¹H NMR δ (ppm) 400MHz (CDCl₃): 1.30 (9 H, s), 2.10-2.17 (2 H, m), 2.35-2.52 (5 H, m), 3.37-3.45 (2 H, m), 4.02-4.06 (2 H, m), 6.34 (1 H, s), 7.14 (1 H, dd, J = 4.7,

7.8Hz), 7.26-7.33 (4 H, m), 7.48 (1 H, d, J = 7.8Hz), 8.35 (1 H, d, J = 4.3Hz). MS_p m/z for MH⁺ = 370.

Example 13 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4-(pentafluoro-λ⁶-sulfanyl)phenyl]piperidine-1-carboxamide

The title compound was obtained using the procedure shown in example 17 using [4-(pentafluoro-λ⁶-sulfanyl)phenyl]amine and Description Example 3.

¹H NMR δ (ppm) 400MHz (DMSO): 2.06-2.12 (2 H, m), 2.17-2.34 (2 H, m), 2.48 (3 H, d, J = 5.5Hz), 3.19-3.27 (2 H, m), 4.1-4.18 (2 H, m) 7.28 (1 H, dd, J = 4.5, 7.6Hz), 7.63-7.70 (3 H, m), 7.75 - 7.78 (2 H, m), 8.37 (1 H, d, J = 4.5Hz), 9.10 (1 H, s). MS_p m/z for MH⁺ = 440.

Example 14 N-(4-Butylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

The title compound was obtained using the procedure shown in Example 10 using 4-n-butylphenyl isocyanate and Description Example 3.

¹H NMR δ (ppm) 400 MHz (CDCl₃): 0.91 (3 H, t, J = 7.2Hz), 1.29-1.39 (2 H, m), 1.53-1.61 (2 H, m), 2.10-2.17 (2 H, m), 2.34-2.58 (7 H, m), 3.37-3.44 (2 H, m), 4.02-4.06 (2 H, m), 6.35 (1 H, s), 7.08-7.14 (3 H, m), 7.24-7.28 (2 H, m), 7.48 (1 H, dd, J = 7.0, 0.8Hz), 8.35 (1 H, d, J = 4.7Hz). MS_p m/z for MH⁺ = 370.

Example 15 N-(4-Benzylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

The title compound was obtained using the procedure shown in Example 10 using 4-benzylphenyl isocyanate and Description Example 3.

¹H NMR δ (ppm) 400MHz (CDCl₃): 2.10-2.17 (2 H, m), 2.34-2.48 (2 H, m), 2.51 (3 H, d, J = 5.5Hz), 3.37-3.44 (2 H, m), 3.94 (2 H, s), 4.01-4.06 (2 H, m), 6.37 (1 H, s), 7.10-7.20 (6 H, m), 7.25-7.30 (4 H, m), 7.47 (1 H, dd, J = 7.4, 0.8Hz), 8.35 (1 H, d, J = 4.7Hz). MS_p m/z for MH⁺ = 404.

Example 16 N-biphenyl-4-yl-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

The title compound was obtained using the procedure shown in example 16 using 4-biphenyl isocyanate and Description Example 3.

¹H NMR δ (ppm) 400MHz (DMSO): 2.04-2.13(2 H, m), 2.18-2.35 (2 H, m), 2.48-2.51(3 H, m), 3.20-3.27 (2 H, m), 4.13-4.16 (2 H, m), 7.26-7.32 (2 H, m), 7.40-7.45 (2 H, m), 7.55-7.65 (7 H, m), 8.38 (1 H, d, $J = 4.7\text{Hz}$), 8.73 (1 H, s) MSp m/z for $\text{MH}^+ = 390$.

5

Example 17 4-Fluoro-4-(3-methylpyridin-2-yl)-*N*-[5-trifluoromethylpyridin-2-yl]piperidine-1-carboxamide

5-Trifluoromethylpyridine-2-carboxylic acid (191mg, 1mmol), diphenyl phosphoryl azide (275mg, 1mmol) and triethylamine(202mg, 2mmol) was heated at 90 °C for 3 hours. Description Example 3 (195mg, 1mmol) was added to the reaction mixture and stirred at room temperature for 72 hours. The reaction mixture was evaporated, partitioned between water (2ml) and dichloromethane (5ml) in a phase separation cartridge. The aqueous phase was washed with more dichloromethane and the combined organics were evaporated. The compound was purified by mass-triggered HPLC to give the desired compound (27mg).

15

¹H NMR δ (ppm) 400MHz(CDCl₃): 2.12-2.22 (2 H, m), 2.36-2.52 (5 H, m), 3.42-3.50 (2 H, m), 4.07-4.13 (2 H, m), 7.14 (1 H, dd, $J = 4.5, 7.6\text{Hz}$), 7.43-7.51 (2 H, m), 7.87 (1 H, dd, $J = 2.3, 8.6\text{Hz}$), 8.19 (1 H, d, $J = 9.0\text{Hz}$), 8.35 (1 H, d, $J = 4.7\text{Hz}$), 8.46 (1 H, s). MSp m/z for $\text{MH}^+ = 383$.

20

Example 18 4-(3-Chloropyridin-2-yl)-4-fluoro-*N*-[4-trifluoromethylphenyl]piperidine-1-carboxamide

1,4-diazabicyclo[2.2.2]octane (3.08g, 27.5mmol) in diethyl ether (110ml) was treated with *n*-butyl lithium in hexanes (17.2ml, 1.6M, 25mmol) at -40 °C keeping the temperature in the range -40 °C to -30 °C, and stirred in this temperature range for 1 hour. The reaction was cooled to -65 °C and 3-chloropyridine (2.84g, 25mmol) was added and stirred at this temperature for 1 hour. The mixture was cooled to -78 °C and 1-*tert*butoxycarbonyl-4-piperidone (4.98g, 25mmol) in diethyl ether (50ml) was added dropwise. After 1 hour at -78 °C, the reaction was allowed to warm to -50 °C over 2 hours. Saturated aqueous ammonium chloride (50ml) was added and the aqueous was extracted using ethyl acetate (4x50ml). The combined organics were dried over sodium sulphate and evaporated. Column chromatography on silica using 5- 20% ethyl acetate in isohexane as eluant gave *tert*-butyl 4-hydroxy-4-(3-chloropyridin-2-yl)piperidine-1-carboxylate

30

contaminated with 1-tertbutoxycarbonyl-4-piperidone (3.31g). This mixture (1.9g) was converted to the desired compound (510mg) using the chemistry described in Description Example 2 and Example 1.

1H NMR δ (ppm) 400MHz (CDCl₃) 2.32-2.50 (4 H, m), 3.45-3.52 (2H, m), 4.02-4.09 (2 H, m), 6.57 (1 H, s), 7.22-7.26 (1 H, m), 7.48-7.56 (4 H, m), 7.76 (1 H, dd, J = 1.4, 8.0Hz), 8.44-8.46 (1 H, m). MSp m/z for MH⁺ = 402.

Example 19 4-Fluoro-4-(3-fluoropyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

The title compound was obtained using the chemistry described in Example 18, using 3-fluoropyridine as the starting material.

H NMR δ (ppm) 400MHz (CDCl₃): 2.27-2.45 (4 H, m), 3.46-3.53 (2 H, m), 4.02-4.07 (2 H, m), 6.57 (1 H, s), 7.31-7.38 (1 H, m), 7.44-7.56 (5 H, m), 8.39 (1 H, d, J = 4.7Hz). MSp m/z for MH⁺ = 386.

Example 20 4-Fluoro-4-(3-methoxypyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

The title compound was prepared from 2-bromo-3-methoxypyridine using the chemistry described for Description Example 1 and Example 1.

1H NMR δ (ppm) 400MHz (CDCl₃): 2.35-2.48 (4 H, m), 3.46-3.53 (2 H, m), 3.89 (3H, s) 3.98-4.03 (2 H, m), 6.57 (1 H, s), 7.27 (2 H, d, J = 2.7Hz), 7.49-7.54 (4H, m), 8.17-8.2 (1 H, m). MSp m/z for MH⁺ = 398.

Example 21 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carbothioamide

The title compound was prepared using the procedure described in Example 10 with Description Example 3) and 4-trifluoromethylphenyl isothiocyanate.

1H NMR δ (ppm) 400MHz (CDCl₃): 2.14-2.21 (2 H, m), 2.47-2.65 (5 H, m), 3.60-3.67 (2 H, m), 4.52-4.58 (2 H, m), 7.15 (1 H, dd, J = 4.7, 7.4Hz), 7.23 (1 H, s), 7.27 (2 H, d, J = 8.2Hz), 7.49 (1 H, dd, J = 7.0, 0.8Hz), 7.60 (2 H, d, J = 8.2Hz), 8.35 (1 H, d, J = 4.7Hz). MSp m/z for MH⁺ = 398.

Example 22 *N*-cyano-4-fluoro-4-(3-methylpyridin-2-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carboximidamide

Example 21 (39.7mg 0.1mmol), cyanamide (310mg, 7.4mmol) and silver acetate (17mg, 0.1mmol) in acetonitrile (3ml) were heated in a pressurized microwave reactor at 140 °C for 10 minutes. The reaction was repeated on twice this scale and the reactions combined. The reactions were combined, evaporated and partitioned between dichloromethane (50ml) and water (50ml). The organics were washed with water (50ml), dried (Na₂SO₄) and evaporated. The desired compound (20mg) was obtained by column chromatography purification on silica using 25%-100% ethyl acetate in isohexane as the eluant.

¹H NMR δ (ppm) 400MHz (CDCl₃): 2.04-2.17 (2 H, m), 2.34-2.54 (5 H, m), 3.35-3.43 (2 H, m), 3.90-3.95 (2 H, m), 7.10-7.16 (3 H, m), 7.18 (1H s) 7.47 (1H d J=7Hz) 7.62 (2 H, d, J = 8.2Hz). 8.34 (1H, d, J=4.7Hz) MSp m/z for MH⁺ =406.

Example 23 4-Fluoro-4-(3-methylpyridin-2-yl)-*N*-(1-phenylpiperidin-4-yl)-*N*-(4-trifluoromethylphenyl)piperidine-1-carboximidamide

Example 21 (397mg, 1mmol), 1-phenylpiperidin-4-ylamine (176mg, 1mmol) and silver acetate (167mg, 1mmol) in acetonitrile (20ml) were heated at reflux overnight. The reaction mixture was evaporated, purified by column chromatography on silica using 2-10% methanol in dichloromethane as the eluant, followed by mass triggered HPLC purification using an acid based eluant. The free base was liberated using a strong cation exchange cartridge to give the desired compound (40mg).

¹H NMR δ (ppm) 400MHz (CDCl₃), 1.45-1.52 (2 H, m), 2.00-2.13 (4 H, m), 2.32-2.52 (5 H, m), 2.74-2.80 (2 H, m), 3.25-3.31 (2 H, m), 3.37-3.46 (1 H, m), 3.55-3.76 (4 H, m), 6.82-6.93 (5 H, m), 7.14 (1 H, dd, J = 4.7, 7.4Hz), 7.23-7.27 (2 H, m), 7.48 - 7.52 (3 H, m), 8.37 (1 H, d, J = 4.3Hz). MSp m/z for MH⁺ =540.

Example 24 4-Fluoro-4-phenyl-*N*-(4-trifluoromethylphenyl)piperidine-1-carboxamide

Using 4-fluoro-4-phenylpiperidine, 4-trifluoromethylphenylisocyanate and the procedure in Example 10 the title compound was obtained.

¹H NMR δ (ppm) 400MHz (MeOD): 1.98-2.24 (4 H, m), 3.34-3.38 (2 H, m), 4.19-4.24 (2 H, m), 7.28-7.32 (1 H, m), 7.38 (2 H, m), 7.43 (2 H, m), 7.54 (2 H, d, J = 8.8Hz), 7.59 (2 H, d, J = 8.7Hz). MSp m/z for MH⁺ =367.

Example 25 (+/-)-(syn)-4-fluoro-2-methyl-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

Step 1: Zinc powder (48g, 734mmoles) was added in a single portion to a stirred solution of 2-methyl-4-oxo-3,4-dihydro-2H-pyridine-1-carboxylic acid methyl ester (11.38g, 67.3mmoles) (Cumins, D. L. and Al-awar, R. S., Journal of Organic Chemistry, 1995, 60, 711-716 using methylmagnesium bromide as the Grignard reagent) in acetic acid (70ml) at room temperature. The reaction was then heated at reflux for 18 hours, cooled, the zinc filtered and washed with acetic acid. The resulting filtrate was evaporated in vacuo to give an orange oil. This was absorbed onto silica and purified by column chromatography on silica using 25% ethyl acetate in isohexane to give 2-methyl-4-oxopiperidine-1-carboxylic acid methyl ester as a clear oil (5.3g, 46% yield).

¹H NMR δ (ppm) 400MHz (DMSO): 1.10 (3 H, d, J = 7.0Hz), 2.15-2.28 (2 H, m), 2.43-2.48 (1 H, m), 2.74 (1 H, dd, J = 6.7, 14.9Hz), 3.34-3.38 (1 H, m), 3.64 (3 H, s), 4.02-4.05 (1 H, m), 4.50-4.54 (1 H, m). MS_{Sp} m/z for MH⁺ = 172.

Step 2: Methyl 4-hydroxy-2-methyl-4-(3-methylpyridin-2-yl)piperidine-1-carboxylate was synthesized in the same manner as Description Example 1 using the product of Step 1 and 2-bromo-3-methylpyridine.

¹H NMR δ (ppm) 400MHz (DMSO): 1.35 (3 H, d, J = 7.0Hz), 1.76-1.83 (2 H, m), 1.98-2.14 (2 H, m), 2.56 (3 H, s), 3.32-3.35 (1 H, m), 3.60 (3 H, s), 3.85-3.91 (1 H, m), 4.28-4.35 (1 H, m), 5.28 (1 H, s), 7.15-7.18 (1 H, m), 7.52-7.54 (1 H, m), 8.29 (1 H, dd, J = 6, 1.3 Hz). MS_{Sp} m/z for MH⁺ = 265.

Step 3: 47% hydrogen bromide in acetic acid (3ml, excess) was added dropwise to a stirred solution of the product of Step 2 (361mg, 1.4mmoles) in acetic acid (1ml) and stirred at room temperature for 48 hours. The reaction was concentrated in vacuo to give a pale brown solid. This was then reacted with 4-trifluoromethylphenylisocyanate using the same procedure as for Example 1 to give crude material which was purified by mass triggered HPLC using an acid based eluant, and strong cation exchange cartridge to give (+/-)-(syn)-4-hydroxy-2-methyl-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide free base as a white solid (256mg, 46%).

1H NMR δ (ppm) 400MHz (DMSO): 1.42 (3 H, d, J = 6.7Hz), 1.84-1.87 (2 H, m), 2.09-2.16 (1 H, m), 2.20-2.34 (1 H, m), 2.58 (3 H, s), 3.38-3.46 (1 H, m), 3.96-4.00 (1 H, m), 4.50-4.53 (1 H, m), 5.31 (1 H, s), 7.16-7.19 (1 H, m), 7.53-7.57 (3 H, m), 7.69 (2 H, d, J = 9.6Hz), 8.31 (1 H, dd, J = 3.9, 0.8Hz), 8.81 (1 H, m). MS_p m/z for MH⁺ = 394.

Step 4: To a suspension of the product of Step 3 (221mg, 0.56mmol) in dichloroethane (10ml) at -78°C diethylaminosulphur trifluoride (144 μ l, 1.18mmol) was added dropwise. Workup was analogous to Description Example 2, to give crude product which was purified via column chromatography on silica using 10-20% ethyl acetate in isohexane to give the desired product (8mg, 4%). 1H NMR δ (ppm) 500MHz (MeOD): 1.15 (3 H, d, J = 6.6Hz), 2.21-2.49 (3 H, m), 2.50 (2 H, s), 2.51 (3 H, d, J = 4.8Hz), 2.58-2.67 (1 H, m), 3.53-3.59 (1 H, m), 4.06-4.11 (1 H, m), 4.38-4.45 (1 H, m), 7.24 (1 H, dd, J = 4.7, 7.6Hz), 7.54 (2 H, d, J = 8.7Hz), 7.60 (2 H, d, J = 8.8Hz), 8.36 (1 H, d, J = 4.6Hz). MS_p m/z for MH⁺ = 396.

Example 26 4-(Fluoromethyl)-4-pyridin-2-yl-*N*-[4-trifluoromethylphenyl]piperidine-1-carboxamide

Step 1: Sodium hydride (60% in mineral oil, 2.04g, 51mmol) was added portion wise over 8 minutes to a stirring solution of 2-pyridineacetonitrile (1.8ml, 17mmol) and *N*-(tert-butyloxycarbonyl)bis(2-chloroethyl)amine in anhydrous DMF (50ml) at 0°C. The reaction was then heated at 60°C for 5 ½ hours. The reaction was cooled and extracted into ethyl acetate (4 x 150ml), and washed with water (3 x 200ml). The organic layer was then dried over anhydrous MgSO₄, filtered and evaporated in vacuo to give a red/black oil. This was absorbed onto silica and purified by column chromatography using 20% ethyl acetate in isohexane to give *tert* butyl 4-cyano-4-pyridin-2-ylpiperidine-1-carboxylate as an orange solid (2.13g, 44%).

1H NMR δ (ppm) 360MHz (CDCl₃): 1.48 (9 H, s), 2.04-2.08 (2 H, m), 2.17-2.25 (2 H, m), 3.15-3.28 (2 H, m), 4.20-4.35 (2 H, m), 7.25-7.29 (1 H, m), 7.61 (1 H, d, J = 8Hz), 7.73-7.78 (1 H, m), 8.61 (1 H, dd, J = 0.7, 3.9Hz). MS_p m/z for MH⁺ = 287 (-56).

Step 2: HCl gas was bubbled through a solution of the product of Step 1 (1g, 3.5mmol) in anhydrous methanol (20ml) for 10 minutes at 0°C. This was warmed to room temperature and stirred for 48 hours, then evaporated in vacuo. The resulting solid (1.03g, 3.5mmol) was suspended in anhydrous dichloroethane (25ml). To the stirring suspension at 0°C triethylamine (1.1ml, 7.7mmol), benzaldehyde (400µl, 3.85mmol) and 3Å molecular sieves (5g) were added and allowed to stirred at room temperature for 15 minutes before sodium cyanoborohydride (242mg, 3.85mmol) was added in a single portion and the solution stirred at room temperature for 18 hours. The solvent was then evaporated *in vacuo*, to the residue water (50ml) was added and extracted into ethyl acetate (2 x 50ml). The organic layer was dried over anhydrous MgSO₄, filtered and evaporated in vacuo to give an orange oil. This was purified by column chromatography on silica using 0-5% methanol in dichloromethane as eluant. This gave methyl 1-benzyl-4-pyridin-2-ylpiperidine-4-carboxylate as an orange oil (820mg, 76%).

¹H NMR δ (ppm) 360MHz (CDCl₃): 2.10-2.1 (2 H, m), 2.23-2.29 (2 H, m), 2.49-2.54 (2 H, m), 2.74-2.77 (2 H, m), 3.47 (2 H, s), 3.69 (3 H, s), 7.16 (1 H, dd, J = 5.1, 7.2Hz), 7.28-7.34 (6 H, m), 7.64 (1 H, td, J = 7.7, 1.7Hz), 8.56 (1 H, dd, J = 0.7, 3.9Hz). MS_p m/z for MH⁺ = 311.

Step 3: Lithium aluminium hydride (1M in tetrahydrofuran, 1ml, 1mmol) was added to a stirred solution of the product of Step 2 (320mg, 1mmol) in anhydrous THF (3ml) at -30°C and stirred at this temperature for 1 hour. Water (2ml) was added then extracted into ethyl acetate (2 x 5ml) organic layers combined, dried over anhydrous MgSO₄, filtered, filtrate evaporated in vacuo to give (1-benzyl-4-pyridin-2-ylpiperidin-4-yl)methanol as an orange oil which solidified on standing (263mg, 93%).

¹H NMR δ (ppm) (CDCl₃): 1.89-1.94 (2 H, m), 2.14-2.21 (2 H, m), 2.43-2.56 (4 H, m), 3.51 (2 H, s), 3.80 (2 H, s), 7.14-7.17 (1 H, m), 7.19-7.34 (5 H, m), 7.37 (1 H, d, J = 8.1Hz), 7.66-7.71 (1 H, m), 8.52 (1 H, dd, J = 0.7, 3.9Hz).

MS_p m/z for MH⁺ = 283.

Step 4: A slurry of 10% palladium on carbon (84mg) was added to a solution of the product of Step 3 (124mg, 0.44mmol) in ethanol (10ml). This was

hydrogenated at room temperature under atmospheric pressure for 72 hours.

The catalyst was filtered, washed with ethanol, and the filtrate concentrated in vacuo. The resulting amine (85mg, 0.44mmol) was dissolved in dichloromethane (10ml), to the stirring solution di-*tert*-butyldicarbonate (95mg, 0.44mmol) added and stirred at room temperature for 2 hours. The reaction was evaporated *in vacuo*, extracted into ethyl acetate and washed with water, then the organic layer dried over MgSO₄, filtered and evaporated to give *tert*-butyl 4-hydroxymethyl-4-pyridin-2-ylpiperidine-1-carboxylate as an off-white solid (120mg, 93%).

¹H NMR δ (ppm) 400MHz (CDCl₃): 1.46 (9 H, s), 1.80-1.86 (2 H, m), 2.07-2.14 (2 H, m), 3.43-3.49 (4 H, m), 3.80 (2 H, bs), 3.94 (1 H, bs), 7.16-7.21 (1 H, m), 7.33 (1 H, d, J = 8.2Hz), 7.68-7.73 (1 H, m), 8.53-8.57 (1 H, m).

MSp m/z for MH⁺ = 237 (-56).

Step 5: Diethylaminosulphur trifluoride (76 μ l, 0.62mmol) was added to a stirring solution of the product of Step 4 (120mg, 0.41mmol) in anhydrous ethyl acetate (3ml) at -78°C. The reaction was allowed to warm to RT overnight. The solution was evaporated and to the resulting oil tetrabutylammonium fluoride (1M solution in tetrahydrofuran, 820 μ l 0.82mmol) added and refluxed for 2 hours. The reaction was cooled to RT water (3ml) added and the aqueous layer was extracted with ethyl acetate (3 x 5ml). The combined organics were dried over MgSO₄, filtered and the filtrate evaporated in vacuo. The resulting oil was stirred in trifluoroacetic acid (1ml) for 1 hour, the solvent then evaporated and the residue dissolved in dichloromethane. To this stirring solution triethylamine (123 μ l, 0.90mmol), and 4-trifluoromethylphenylisocyanate (59 μ l, 0.41mmol) were added and the solution stirred at room temperature for 18 hours. The reaction was evaporated, water (5ml) added and extracted with ethyl acetate (3 x 5ml). The combined organics were evaporated to give an oily orange compound. This was washed with dichloromethane and purified on a silica prep plate using 5% methanol in dichloromethane with 0.1% ammonia as the eluant. This gave the desired compound as a white solid (1.8mg, 1%).

¹H NMR δ (ppm) 500MHz (MeOD): 1.89-1.94 (2 H, m), 2.48-2.51 (2 H, m), 3.08-3.15 (2 H, m), 3.92-3.97 (2 H, m), 4.45 (2 H, d, J = 48Hz), 7.28-7.30 (1 H, m), 7.51-7.67 (5 H, m), 7.80-7.84 (1 H, m), 8.60-8.61 (1 H, m).MSp m/z for MH⁺ = 382.

Examples 27 and 28 *Syn- and Anti*-3-fluoro-3-pyridin-2-yl-*N*-[4-trifluoromethylphenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide & 3-fluoro-3-pyridin-2-yl-*N*-[4-trifluoromethylphenyl]-8-azabicyclo[3.2.1]octane-8-carboxamide

- 5 Step 1: 2-Lithiopyridine was added to *tert*-butoxycarbonyltropinone according to the procedure in Description Example 1 to give 3-hydroxy-3-pyridin-2-yl-8-azabicyclo[3.2.1]octane-8-carboxylic acid *tert*-butyl ester. Without complete purification, the product was treated according to the procedure in Description Example 2 to give 3-fluoro-3-pyridin-2-yl-8-azabicyclo[3.2.1]octane-8-carboxylic acid *tert*-butyl ester as a 1.2:1 mixture of *syn:anti* isomers. *Syn*: ¹H NMR δ (ppm) 500MHz(CDCl₃): 1.50 (9 H, s), 1.88-2.19 (4 H, m), 2.33 (2 H, m), 2.68 (2 H, m), 4.47 (2 H, m), 7.15 (1 H, m), 7.49 (1 H, m), 7.67 (1 H, m), 8.52 (1 H, m). MSp m/z for MH⁺ =307. *Anti*: ¹H NMR δ (ppm) 500MHz(CDCl₃): 1.51 (9 H, s), 1.93 (2 H, m), 2.33 (2 H, m), 2.59 (4 H, m), 4.47 (2 H, m), 7.22 (1 H, m), 7.62 (1 H, m), 7.71 (1 H, m), 8.56 (1 H, m). MSp m/z for MH⁺ =307.
- 10
- 15

- Step 2a: The major isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 27). ¹H NMR δ (ppm) 700MHz(CDCl₃): 2.07 (2 H, d, J 16.8 Hz), 2.14 (2 H, m), 2.33 (2 H, dd, J 14.0, 6.3 Hz), 2.75 (2 H, m), 4.51 (2 H, brs), 6.58 (1 H, s), 7.21 (1 H, m), 7.50 (1 H, m), 7.56 (4 H, m), 7.73 (1 H, m), 8.53 (1 H, m). MSp m/z for MH⁺ =394.
- 20

- Step 2b: The minor isomer of the product of Step 1 was treated according to the procedure in Example 1 to give the title compound (Example 28). ¹H NMR δ (ppm) 700MHz(CDCl₃): 1.80 (2 H, dd, J 14.0, 6.3 Hz), 2.07 (2 H, dd, J 7.0, 3.5 Hz), 2.60 (4 H, m), 4.48 (2 H, brs), 6.56 (1 H, s), 7.25 (1 H, m), 7.55 (2 H, d, J 9.1 Hz), 7.57 (2H, d, J 9.1 Hz), 7.61 (1 H, m), 7.74 (1 H, m), 8.58 (1 H, m). MSp m/z for MH⁺ =394.
- 25

- 30 Example 29 4-Fluoro-4-pyrimidin-2-yl-*N*-[4-trifluoromethylphenyl]piperidine-1-carboxamide

Step 1: 4-Hydroxy-4-pyrimidin-2-ylpiperidine-1-carboxylic acid *tert*-butyl ester was prepared according to WO-A-9903847 and then treated according to the

procedure in Description Example 2 to give 4-fluoro-4-pyrimidin-2-ylpiperidine-1-carboxylic acid *tert*-butyl ester.

¹H NMR δ (ppm) 400MHz(CDCl₃): 1.48 (9 H, s), 2.08-2.34 (4 H, m), 3.27 (2 H, m), 4.08 (2 H, m), 7.27 (1 H, t, J 4.7 Hz), 8.79 (2 H, d, J 4.7 Hz).

5

Step 2: The product of Step 1 was treated according to the procedure in Example 1 to give the title compound.

¹H NMR δ (ppm) 500MHz(CDCl₃): 2.25-2.44 (4 H, m), 3.49 (2 H, m), 4.07 (2 H, m), 6.56 (1 H, s), 7.29 (1 H, t, J 4.8 Hz), 7.49 (2 H, d, J 8.7), 7.55 (2 H, d, J 8.7), 8.81 (2 H, d, J 4.8 Hz). MSp m/z for MH⁺ =369.

10

Example 30 4-Fluoro-4-(3-phenylpropyl)-N-[4-trifluoromethylphenyl]piperidine-1-carboxamide

The title compound was prepared using a procedure analogous to that in Example 7 using 4-fluoro-4-(3-phenylpropyl)piperidine hydrochloride as the amine.

15

¹H NMR δ (ppm) 400MHz(DMSO): 1.43-1.82 (8H, m), 2.53-2.63 (2 H, m), 3.03-3.10 (2 H, m), 3.92-3.98 (2 H, m), 7.14-7.23 (3 H, m), 7.26-7.30 (2 H, m), 7.57 (2H, d J=8.6Hz), 7.68 (2H, d J=8.6Hz), 8.91 (1 H, s). MSp m/z for MH⁺ =409.

20

Example 31 2-[4-Fluoro-4-(3-methylpyridin-2-yl)piperidin-1-yl]-6-trifluoromethyl-1H-benzimidazole

Description Example 3 (87.2mg, 0.46mmol) was treated with ethanol (1ml) and 2-chloro-5-(trifluoromethyl)-1H-benzimidazole (100mg, 0.46mmol) (WO-A-021471) and heated in a pressurized microwave vessel at 160°C for 10 minutes. After evaporation, the compound was purified by column chromatography using 2-5% methanol in dichloromethane as the eluant to give 2-[4-hydroxy-4-(3-methylpyridin-2-yl)piperidin-1-yl]-6-trifluoromethyl-1H-benzimidazole (18mg) (MSp m/z for MH⁺ =377). This was converted to the title compound using the procedure outlined in Description Example 2.

25

30

¹H NMR δ (ppm) 400 MHz (DMSO): 1.9-2.05 (2H, m), 2.508-2.27(2 H, m), 2.32 - 2.34(3 H, m), 3.20-3.32 (2 H, m), 3.96-4.03 (2H, m), 7.04-7.21 (3 H, m), 7.23-7.35 (1 H, m), 7.48 (1H, d J=6.7Hz), 8.17 (1H, d J=4.3Hz), 11.67-11.72 (1 H, m). MSp m/z for MH⁺ =379.

Example 32 2-(4-Fluoro-4-pyridin-2-yl)piperidin-1-yl)-6-(trifluoromethyl)-1H-benzimidazole

The title compound was prepared using a procedure analogous to that in

5 Example 31 from Description Example 4.

¹H NMR δ (ppm) (CDCl₃): 2.02-2.07 (2 H, m), 2.41-2.59 (2 H, m), 3.56-3.61 (2 H, m), 4.10-4.13 (2 H, m), 7.22-7.59 (6 H, m), (7.73-7.79 (1 H, m), 8.52-8.53 (1 H, m).

MSP m/z for MH⁺ = 365.

10 Example 33 4-Fluoro-N-[4-trifluoromethylphenyl]-4-[3-trifluoromethylpyridin-2-yl]piperidine-1-carboxamide

2-bromo-3-trifluoromethylpyridine (1.13g, 5mmol) and 1-butoxycarbonyl-4-piperidone (1g, 5mmol) in THF(20ml) was cooled to -78°C and tert-butyllithium (4.4ml, 1.7M in pentane, 7.5mmol) was added dropwise to this solution. After

15 stirring at this temperature for 30 minutes, the reaction mixture was allowed to warm to room temperature over two hours. Water (50ml) was added and the aqueous was extracted using ethyl acetate (3 x 50ml). The combined organics were dried over sodium sulphate and evaporated. Column chromatography on silica using 10-20% ethyl acetate in isohexane as eluant gave *tert*-butyl 4-

20 hydroxy-4-(3-trifluoromethylpyridin-2-yl)piperidine-1-carboxylate contaminated with 1-butoxycarbonyl-4-piperidone (650mg). This mixture was converted to the desired compound using the chemistry described in Description Example 2 and Example 1.

¹H NMR δ (ppm) 400MHz (CDCl₃) 2.13-2.05 (2 H, m), 2.60-2.42 (2 H, m), 3.46-3.40 (2 H, m), 4.11 (2 H, dd, J = 4.8, 13.4 Hz), 6.61 (1 H, s), 7.42-7.36 (1 H, m), 7.48-7.57 (4 H, m), 8.11 (1 H, d, J = 8.0 Hz), 8.70 (1 H, d, J = 4.6 Hz). MSP m/z for MH⁺ = 436.

Examples 34 to 39 were made using the procedure shown in Example 10 using

30 Description Example 3 and 4-tolyl isocyanate, 4-ethylphenyl isocyanate, 4-chlorophenyl isocyanate, 4-trifluoromethoxy isocyanate, 4-cyanophenyl isocyanate and 4-dimethylaminophenyl isocyanate respectively.

Example 34 4-Fluoro-N-(4-methylphenyl)-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

1H NMR δ (ppm) 400MHz(CDCl₃): 2.11-2.17 (2 H, m), 2.30 (3 H, s), 2.50 (5 H, m), 3.38-3.44 (2 H, m), 4.03-4.15 (2 H, m), 6.34 (1 H, s), 7.10-7.14 (3 H, m), 7.23-7.26 (2 H, m), 7.48 (1 H, d, J = 8 Hz), 8.35 (1 H, d, J = 4.6 Hz). MS_p m/z for MH⁺ = 328.

Example 35 N-(4-ethylphenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

10 1H NMR δ (ppm) 360MHz (CDCl₃): 1.21 (3 H, t, J = 7.6 Hz), 2.11-2.17 (2 H, m), 2.34-2.52 (5 H, m), 2.6 (2H, q, J=7.6Hz) 3.37-3.45 (2 H, m), 4.02-4.08 (2 H, m), 6.36 (1 H, s), 7.12-7.14 (3 H, m), 7.25-7.28 (2 H, m) 7.48 (1 H, d, J = 7.0 Hz), 8.36 (1 H, d, J = 4.6 Hz). MS_p m/z for MH⁺ = 342.

15 **Example 36** N-(4-chlorophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

1H NMR δ (ppm) 360MHz (CDCl₃): 2.12-2.18 (2 H, m), 2.34-2.52 (5 H, m), 3.38-3.46 (2 H, m), 4.04 (2 H, d, J = 13.4 Hz), 6.42 (1 H, s), 7.14 (1 H, dd, J = 4.7, 7.7 Hz), 7.24-7.28 (2 H, m), 7.30-7.34 (2 H, m) 7.49 (1 H, d, J = 7.7 Hz), 8.35 (1 H, d, J = 4.7 Hz). MS_p m/z for MH⁺ = 348.

Example 37 4-Fluoro-4-(3-methylpyridin-2-yl)-N-[4-trifluoromethoxyphenyl]piperidine-1-carboxamide

25 1H NMR δ (ppm) 360 MHz (CDCl₃): 2.12-2.20 (2 H, m), 2.34-2.53 (5 H, m), 3.39-3.47 (2 H, m), 4.01-4.09 (2 H, m), 6.46 (1 H, s), 7.12-7.18 (3 H, m), 7.37-7.41 (2 H, m), 7.49 (1 H, d, J = 7.7 Hz), 8.36 (1 H, d, J = 4.8 Hz). MS_p m/z for MH⁺ = 398.

Example 38 N-(4-cyanophenyl)-4-fluoro-4-(3-methylpyridin-2-yl)piperidine-1-carboxamide

30 1H NMR δ (ppm) 360 MHz (CDCl₃): 2.11-2.22 (2 H, m), 2.35-2.53 (5 H, m), 3.41-3.49 (2 H, m), 4.02-4.11 (2 H, m), 6.68 (1 H, s), 7.15 (1 H, dd, J = 4.7, 7.7 Hz), 7.49-7.59 (5 H, m), 8.35 (1 H, d, J = 4.6 Hz). MS_p m/z for MH⁺ = 339.

Example 39 N-[4-dimethylaminophenyl]-4-fluoro-4-(3-methylpyridin-2-yl)
piperidine-1-carboxamide

1H NMR δ (ppm) 400MHz (DMSO): 2.01-2.08 (2 H, t, $J = 12.1$ Hz), 2.16-2.33 (2 H, m), 2.49 (3 H, d $J=5.4$ Hz), 2.87 (6 H, s), 3.12-3.25 (2 H, m), 4.06-4.16 (2 H, m),
5 6.74 (2 H, s), 7.27-7.31 (5 H, m) , 7.66 (1 H, d, $J = 6.9$ Hz), 8.33-8.41 (2 H, m). MS_p
m/z for MH⁺ =357.

